E7777 9 mcg/kg

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Drug Information

Target Indication

Persistent or Recurrent Cutaneous T-Cell Lymphoma

Clinical Trial

Last updated: 12/24/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

ESALY

Eisai

Related Pipeline

Acute Musculoskeletal Spasm Due to Low Back Pain

Rheumatoid Arthritis

Primary Insomnia

Gastric or Duodenal Ulcers Caused by Low-dose Aspirin

Chronic Hepatitis B